Slow, costly process stymies generic biotech drugs – msnbc.com

March 5, 2012 Posted By: Leave a comment
"We don't have that today." The U.S. healthcare law in 2010 stipulated that regulators establish a process for approving lower-cost copies of biotech drugs - often referred to as "biosimilars" because they are not made from the same living cell line as the ...
Subscribe to LegalLaw247.Com Newsletter

Leave a Reply

Your email address will not be published. Required fields are marked *

*

CAPTCHA Image

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>